Mesenchymal stromal cell secretome in liver failure: Perspectives on COVID-19 infection treatment
Open Access
- 7 May 2021
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 27 (17), 1905-1919
- https://doi.org/10.3748/wjg.v27.i17.1905
Abstract
Due to their immunomodulatory potential and release of trophic factors that promote healing, mesenchymal stromal cells (MSCs) are considered important players in tissue homeostasis and regeneration. MSCs have been widely used in clinical trials to treat multiple conditions associated with inflammation and tissue damage. Recent evidence suggests that most of the MSC therapeutic effects are derived from their secretome, including the extracellular vesicles, representing a promising approach in regenerative medicine application to treat organ failure as a result of inflammation/fibrosis. The recent outbreak of respiratory syndrome coronavirus, caused by the newly identified agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has forced scientists worldwide to use all available instruments to fight the infection, including the inflammatory cascade caused by this pandemic disease. The use of MSCs is a valid approach to combat organ inflammation in different compartments. In addition to the lungs, which are considered the main inflammatory target for this virus, other organs are compromised by the infection. In particular, the liver is involved in the inflammatory response to SARS-CoV-2 infection, which causes organ failure, leading to death in coronavirus disease 2019 (COVID-19) patients. We herein summarize the current implications derived from the use of MSCs and their soluble derivatives in COVID-19 treatment, and emphasize the potential of MSC-based therapy in this clinical setting.Keywords
This publication has 123 references indexed in Scilit:
- Mesenchymal-Stem-Cell-Induced Immunoregulation Involves FAS-Ligand-/FAS-Mediated T Cell ApoptosisCell Stem Cell, 2012
- Risk factors in the development of stem cell therapyJournal of Translational Medicine, 2011
- Intravenous N-Acetylcysteine Improves Transplant-Free Survival in Early Stage Non-Acetaminophen Acute Liver FailureGastroenterology, 2009
- Mesenchymal Stem Cell-Derived Microvesicles Protect Against Acute Tubular InjuryJournal of the American Society of Nephrology, 2009
- IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host diseaseEuropean Journal of Immunology, 2008
- Immunomodulation of activated hepatic stellate cells by mesenchymal stem cellsBiochemical and Biophysical Research Communications, 2007
- ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway EpitheliaJournal of Virology, 2005
- Apoptosis: a mechanism of acute and chronic liver injuryGut, 2005
- Fatal Severe Acute Respiratory Syndrome Is Associated with Multiorgan Involvement by CoronavirusThe Journal of Infectious Diseases, 2005
- Human Adipose Tissue Is a Source of Multipotent Stem CellsMolecular Biology of the Cell, 2002